As per DelveInsight’s Warm Autoimmune hemolytic Anemia epidemiology forecast and analysis, Warm Autoimmune hemolytic Anemia prevalence in the 7MM was estimated to be around 82,045 cases.
Despite being a prevalence of 82,045 in the 7MM in 2017, there is no validated and standard FDA-approved therapeutic option available in the wAIHA therapy market.
It poses a considerable burden on the global healthcare system, with most Warm Autoimmune hemolytic Anemia patients not been able to achieve a standard cure.
However, to redress the current unmet needs in the Warm Autoimmune hemolytic Anemia therapy market, many pharma and biotech companies are working to advance the wAIHA market with several products in the pipeline which is expected to positively shirt the Warm Autoimmune hemolytic Anemia therapy market in upcoming years.
For more details visit: https://www.delveinsight.com/blog/warm-autoimmune-ahemolytic-anemia-epidemiology-forecast/